EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repaglinide Induces ATF6 Processing and Neuroprotection in Transgenic SOD1G93A Mice

Rafael Gonzalo-Gobernado iD, Laura Moreno-Martínez iD, Paz González, Xose Manuel Dopazo, Ana Cristina Calvo iD, Isabel Pidal-Ladrón de Guevara, Elisa Seisdedos, Rodrigo Díaz-Muñoz iD, Britt Mellström, Rosario Osta iD, José Ramón Naranjo

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242115783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Rafael Gonzalo-Gobernado und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Biotechnology (CNB), Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Biomedical Research Networking Center on Neurodegenerative Diseases, Instituto de Salud Carlos III CIBERNED.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The interaction of the activating transcription factor 6 (ATF6), a key effector of the unfolded protein response (UPR) in the endoplasmic reticulum, with the neuronal calcium sensor Downstream Regulatory Element Antagonist Modulator (DREAM) is a potential therapeutic target in neurodegeneration. Modulation of the ATF6–DREAM interaction with repaglinide (RP) induced neuroprotection in a model of Huntington’s disease. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no cure, characterized by the progressive loss of motoneurons resulting in muscle denervation, atrophy, paralysis, and death. The aim of this work was to investigate the potential therapeutic significance of DREAM as a target for intervention in ALS. We found that the expression of the DREAM protein was reduced in the spinal cord of SOD1G93A mice compared to wild-type littermates. RP treatment improved motor strength and reduced the expression of the ALS progression marker collagen type XIXα1 (Col19α1 mRNA) in the quadriceps muscle in SOD1G93A mice. Moreover, treated SOD1G93A mice showed reduced motoneuron loss and glial activation and increased ATF6 processing in the spinal cord. These results indicate that the modulation of the DREAM–ATF6 interaction ameliorates ALS symptoms in SOD1G93A mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisMiceAnimalsMice, TransgenicActivating Transcription Factor 6NeuroprotectionMotor NeuronsKv Channel-Interacting ProteinsSuperoxide DismutaseDisease Models, AnimalCarbamatesPiperidines

Stichwörter der Autor:innen

ALSATF6DREAMSOD1UPRastrogliamicrogliamotoneuronsrepaglinide

Substanzen

Activating Transcription Factor 6Kv Channel-Interacting ProteinsSuperoxide DismutaserepaglinideCarbamatesPiperidines

Autor:innen und Institutionen

  • National Centre for Biotechnology (CNB), Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain.
  • Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • LAGENBIO, Faculty of Veterinary, University of Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain.
  • Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), 50009 Zaragoza, Spain.
  • AgriFood Institute of Aragon-IA2 (UNIZAR-CITA), 50013 Zaragoza, Spain.

ORCID-Profile: Rafael Gonzalo-Gobernado, Laura Moreno-Martínez, Ana Cristina Calvo, Rodrigo Díaz-Muñoz, Rosario Osta

Förderung

  • Instituto de Salud Carlos III
  • Biomedical Research Networking Center on Neurodegenerative Diseases
  • Instituto de Salud Carlos III CIBERNED
  • Fondo Europeo de Desarrollo Regional (FEDER)
  • Gobierno de Aragón
  • Asahi Kasei Pharma (JRN)
  • Severo Ochoa Excellence Program

Zitieren

APA

Gonzalo-Gobernado, R., Moreno-Martínez, L., González, P., Dopazo, X. M., Calvo, A. C., Pidal-Ladrón de Guevara, I., Seisdedos, E., Díaz-Muñoz, R., Mellström, B., Osta, R., & Naranjo, J. R. (2023). Repaglinide Induces ATF6 Processing and Neuroprotection in Transgenic SOD1G93A Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242115783

Vancouver

Gonzalo-Gobernado R, Moreno-Martínez L, González P, Dopazo XM, Calvo AC, Pidal-Ladrón de Guevara I, et al. Repaglinide Induces ATF6 Processing and Neuroprotection in Transgenic SOD1G93A Mice. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242115783

BibTeX
@article{GonzaloGobernado2023,
  author = {Gonzalo-Gobernado, Rafael and Moreno-Martínez, Laura and González, Paz and Dopazo, Xose Manuel and Calvo, Ana Cristina and Pidal-Ladrón de Guevara, Isabel and Seisdedos, Elisa and Díaz-Muñoz, Rodrigo and Mellström, Britt and Osta, Rosario and Naranjo, José Ramón},
  title = {Repaglinide Induces ATF6 Processing and Neuroprotection in Transgenic SOD1G93A Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242115783}
}
Kostenlos starten →